Ajanta Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Ajanta Pharma is an Indian medicine company that makes and sells medicines. It mainly sells branded generic medicines in India and developing markets like Africa and Southeast Asia, and generic medicines in the USA. The company mostly works on medicines for heart problems, skin diseases, eye care, and pain relief, and has also started making medicines for kidney and women’s health issues. It is known for its strong research team, quick launch of new medicines, and focus on difficult treatments.
- 1 What is Ajanta Pharma Ltd NSE: AJANTPHARM?
- 2 Ajanta Pharma Share Price Target
- 3 Ajanta Pharma Share Price Target 2025
- 4 Ajanta Pharma India Share Price Target 2026
- 5 Share Price Target 2027
- 6 Share Price Target 2028
- 7 Share Price Target 2029
- 8 Ajanta Pharma share price Target 2030
- 9 Share Price Target 2040
- 10 Share Price Target 2050
- 11 Should I buy Ajanta Pharma stock?
- 12 Ajanta Pharma earnings results
- 13 Is Ajanta Pharma stock good to buy? (bull case & bear case)
- 14 Conclusion
- 15 FAQs
What is Ajanta Pharma Ltd NSE: AJANTPHARM?
Ajanta Pharma is an Indian medicine company established in 1973, situated in Mumbai and started by Y. K. Doshi. The company makes and sells prescription medicines in India and many other countries. It mainly focuses on branded generic medicines used for heart problems, skin diseases, eye care, pain relief, and infections. It also sells generic medicines in the US and other global markets. It is known for good-quality medicines, strong research, and modern factories in India, and a big part of its income comes from exports.
It is a well-known Indian pharmaceutical company that develops and markets medicines for various health conditions. It focuses on making good and safe medicines that doctors trust, and patients can use easily. It does not copy other medicines; it tries to make better and useful ones. The company sells its medicines in more than 30 countries, including India, Africa, Southeast Asia, and the United States. In 2025, its share price target would be ₹3094, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2327 to ₹3094 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 2327 | 3094 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2533 | 3094 |
| February | 2450 | 3079 |
| March | 2380 | 2881 |
| April | 2327 | 2829 |
| May | 2468 | 2699 |
| June | 2506 | 2764 |
| July | 2494 | 2875 |
| August | 2449 | 2792 |
| September | 2329 | 2627 |
| October | 2379 | 2511 |
| November | 2445 | 2622 |
| December | 2550 | 2815 |
The company has a large research team with more than 850 scientists. These scientists work on making new and better medicines like tablets, capsules, syrups, creams, and eye drops. It mainly makes complex medicines that are hard to develop. Many of its medicines are launched first in the market, which helps the company stay ahead of others. In 2026, its share price target would be ₹3911, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2600 to ₹3911 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 2600 | 3911 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2600 | 2921 |
| February | 2735 | 3024 |
| March | 2778 | 3084 |
| April | 2820 | 3155 |
| May | 2859 | 3221 |
| June | 2915 | 3274 |
| July | 2955 | 3325 |
| August | 3058 | 3557 |
| September | 3254 | 3687 |
| October | 3357 | 3778 |
| November | 3558 | 3868 |
| December | 3714 | 3911 |
It has seven modern factories in India. These factories use advanced machines to make medicines safely and in large amounts. Six factories make finished medicines, and one factory makes key raw materials used in medicines. Some factories meet international quality rules and are approved by global health authorities. Because of this, it sells its medicines in strict markets like the United States. In 2027, its share price target would be ₹4688, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3790 to ₹4688 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 3790 | 4688 |
Every medicine made by the company is checked many times before it reaches patients. The company follows strict quality rules to make sure medicines are safe and effective. Its employees are trained regularly to follow proper production and testing steps. It gains trust from doctors, hospitals, and patients. In 2028, its share price target would be ₹5407, as per stock market analysts.
According to stock market analysts, its share price would be between ₹4521 to ₹5407 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 4521 | 5407 |
It is known for its strong branded generic medicines. Branded generics are medicines sold with a brand name that doctors know and trust. It has launched many branded medicines in India across different treatment areas. The company’s medical teams work closely with doctors to explain how the medicines help patients. In 2029, its share price target would be ₹6110, as per stock market analysts.
According to stock market analysts, its share price would be between ₹5347 to ₹6110 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 5347 | 6110 |
It mainly works in selected treatment areas where patient need is high. These include heart care, skin care, eye care, and pain relief. The company has also started making medicines for kidney problems and women’s health. It gains strong knowledge and makes better medicines. This focused approach helps the company build strong brands and stay ahead in its key areas. In 2030, its share price target would be ₹6844, as per stock market analysts.
According to stock market analysts, its share price would be between ₹6058 to ₹6844 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 6058 | 6844 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 6058 | 6187 |
| February | 6074 | 6211 |
| March | 6120 | 6258 |
| April | 6158 | 6314 |
| May | 6190 | 6390 |
| June | 6225 | 6445 |
| July | 6332 | 6512 |
| August | 6384 | 6558 |
| September | 6445 | 6678 |
| October | 6514 | 6712 |
| November | 6582 | 6768 |
| December | 6635 | 6844 |
It has more than 11,000 employees working in different countries. These employees include scientists, factory workers, sales staff, and support teams. The company believes its employees are its biggest strength. It encourages teamwork, honesty, and responsibility at work. Employees are given training to improve their skills. A good work environment helps employees do better work and supports the company’s long-term growth. In 2040, its share price target would be ₹11600, as per stock market analysts.
According to stock market analysts, its share price would be between ₹10840 to ₹11600 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 10840 | 11600 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 10840 | 10988 |
| February | 10874 | 11067 |
| March | 10890 | 10155 |
| April | 10925 | 10225 |
| May | 10978 | 10278 |
| June | 11078 | 10325 |
| July | 11145 | 10378 |
| August | 11190 | 10425 |
| September | 11256 | 10484 |
| October | 11357 | 10523 |
| November | 11451 | 10557 |
| December | 11480 | 11600 |
The company’s main aim is to improve people’s lives by providing safe and effective medicines. The company wants to make healthcare available to more people around the world. Its long-term goal is to become a trusted global medicine company known for quality and innovation. These goals guide the company’s decisions in research, manufacturing, and growth. In 2050, its share price target would be ₹15452, as per stock market analysts.
According to stock market analysts, its share price would be between ₹14653 to ₹15452 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 14653 | 15452 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 14653 | 14825 |
| February | 14685 | 14878 |
| March | 14785 | 14954 |
| April | 14825 | 14990 |
| May | 14880 | 15078 |
| June | 14958 | 15135 |
| July | 14988 | 15190 |
| August | 15057 | 15257 |
| September | 15124 | 15278 |
| October | 15178 | 15300 |
| November | 15251 | 15355 |
| December | 15287 | 15452 |
Should I buy Ajanta Pharma stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 2327 | 3094 |
| 2026 | 2600 | 3911 |
| 2027 | 3790 | 4688 |
| 2028 | 4521 | 5407 |
| 2029 | 5347 | 6110 |
| 2030 | 6058 | 6844 |
| 2040 | 10840 | 11600 |
| 2050 | 14653 | 15452 |
It makes important medicines for heart care, skin, eye, and other long-term health problems, and it focuses on research and high-quality products. Its medicines are trusted by doctors and sold in more than 30 countries, showing a strong global presence. This stock is better for investors looking for steady, long-term growth rather than quick profits, and it should fit your personal goals and comfort with risk before making any decision.
Ajanta Pharma earnings results
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
| Sales + | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 4,973 |
| Expenses + | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,379 | 3,676 |
| Operating Profit | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,297 |
| OPM % | 26% | 35% | 28% | 22% | 28% | 27% | 26% |
| Other Income + | 88 | 24 | 112 | 74 | 85 | 85 | 134 |
| Interest | 12 | 8 | 10 | 6 | 7 | 21 | 23 |
| Depreciation | 96 | 116 | 125 | 131 | 135 | 144 | 160 |
| Profit before tax | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,249 |
| Tax % | 30% | 27% | 22% | 21% | 27% | 23% | |
| Net Profit + | 468 | 654 | 713 | 588 | 816 | 920 | 974 |
| EPS in Rs | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 77.94 |
| Dividend Payout % | 24% | 13% | 11% | 15% | 79% | 38% | — |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 34.13 | 8.77 | 1.06% | 36.65 | 5.78 | 0.59% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Div. Yield |
| Ajanta Pharma Ltd | 36.10 | 8.77 | 1.06% |
| Sun Pharmaceutical Industries Ltd | 39.37 | 5.94 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.14 | 16.91 | 0.84% |
| Cipla Ltd | 23.25 | 3.92 | 1.05% |
Is Ajanta Pharma stock good to buy? (bull case & bear case)
Bull Case:
- Its total revenue from operations was about ₹4,648 crore in FY25, showing good growth from last year.
- The company reported EBITDA of around ₹1,260 crore in FY25, which means it earned well before paying interest and taxes.
- Net profit in FY25 was about ₹920 crore, higher than the previous year, showing steady earnings.
- In Q2 FY26, profit after tax reached ₹260 crore, up about 20% compared with the same quarter last year, showing strong quarterly performance.
- The company declared an interim dividend of ₹28 per share, showing it shares profits with its investors.
- Ajanta Pharma generated strong cash from operations of over ₹1,157 crore in FY25, showing good cash flow.
- The company has no long-term debt, which lowers financial risk and makes the balance sheet strong.
Bear Case:
- Net profit margin was around ~19.8% in FY25, showing some pressure on profitability.
- In certain quarters, EBITDA margins went down slightly, indicating that profits are not increasing as fast as sales.
- The stock trades at higher valuation multiples, which can limit how much the price can go up.
Conclusion
It is an Indian medicine company that sells its medicines in India and more than 30 other countries, including the US, Africa, and Southeast Asia. It mainly makes medicines for heart problems, skin, eyes, pain, kidneys, and women’s health. The company is known for strong research, modern factories, and bringing new medicines to the market quickly. It has no long-term debt and earns steady profits. It is suitable for investors who want safe, long-term growth and a trusted global company.
